We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
신규 편입 · 포트폴리오 비중 0.00%
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $7.6 · 5 analysts
Stored first · Google News · Yahoo Finance (English)
Aldeyra Therapeutics Seeks FDA Clarification on Reproxalap NDA Meeting Minutes
Aldeyra Therapeutics (NASDAQ: ALDX) advances FDA dialogue on reproxalap NDA - Stock Titan
Aldeyra Therapeutics (NASDAQ: ALDX) advances FDA dialogue on reproxalap NDA Stock Titan
Understanding the Setup: (ALDX) and Scalable Risk - Stock Traders Daily
Understanding the Setup: (ALDX) and Scalable Risk Stock Traders Daily
Aldeyra Therapeutics: What Comes Next After Reproxalap's Third CRL (NASDAQ:ALDX) - Seeking Alpha
Aldeyra Therapeutics: What Comes Next After Reproxalap's Third CRL (NASDAQ:ALDX) Seeking Alpha
ALDX FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026 - AOL.com
ALDX FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026 AOL.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Shareholders to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Shareholders to Connect ACCESS Newswire
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 06. | After market close (AMC) | $-0.09 | — | — | $0 | — | Scheduled |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 03. 18. | HC Wainwright & Co. | — | Downgrade | Buy → Neutral | — | HC Wainwright & Co.: Buy → Neutral |
| 2025. 11. 10. | BTIG | — | Maintain | Buy → Buy | — | BTIG: Buy |
| 2025. 05. 19. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2025. 04. 08. | BTIG | — | Maintain | Buy → Buy | — | BTIG: Buy |
| 2025. 04. 04. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2025. 03. 03. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
As of FY2026Q1 · Source: SEC/DART + price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 287,364 | $1.49M | 0.00% | — | New position |
| 2 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 94,094 | $487.41K | 0.00% | — | New position |
| 3 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 223,537 | $377.78K | 0.00% | — | New position |